HIV postexposure prophylaxis-in-pocket

doi:10.1503/cmaj.240064

. 2024 Jul 1;196(24):E826.

doi: 10.1503/cmaj.240064.

HIV postexposure prophylaxis-in-pocket

Maxime Billick¹, Isaac I Bogoch²

Affiliations

¹ Department of Medicine and Division of Infectious Diseases, University of Toronto, Toronto, Ont.
² Department of Medicine and Division of Infectious Diseases, University of Toronto, Toronto, Ont. isaac.bogoch@uhn.ca.

PMID: 38955414
PMCID: PMC11230675
DOI: 10.1503/cmaj.240064

HIV postexposure prophylaxis-in-pocket

Maxime Billick et al. CMAJ. 2024.

. 2024 Jul 1;196(24):E826.

doi: 10.1503/cmaj.240064.

Authors

Maxime Billick¹, Isaac I Bogoch²

Affiliations

¹ Department of Medicine and Division of Infectious Diseases, University of Toronto, Toronto, Ont.
² Department of Medicine and Division of Infectious Diseases, University of Toronto, Toronto, Ont. isaac.bogoch@uhn.ca.

PMID: 38955414
PMCID: PMC11230675
DOI: 10.1503/cmaj.240064

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests:: Maxime Billick reports consulting fees from the Ontario Dermatologic Nurses’ Association. Isaac Bogoch reports consulting fees from the Weapons Threat Reduction Program, Global Affairs Canada. No other competing interests were declared.

References

1. Billick MJ, Sheps J, Bogoch II. HIV prevention with postexposure prophylaxis-in-pocket (PIP). BMJ 2023;382:e076016. doi:10.1136/bmj-2023-076016. - DOI - PubMed
1. Billick MJ, Fisher KN, Myers S, et al. . Brief report: Outcomes of individuals using HIV postexposure prophylaxis-in-pocket (“PIP”) for low-frequency, high-risk exposures in Toronto, Canada. J Acquir Immune Defic Syndr 2023;94:211–3. - PubMed
1. Mayer KH, Gelman M, Holmes J, et al. . Safety and tolerability of once daily coformulated bictegravir, emtricitabine, and tenofovir alafenamide for postexposure prophylaxis after sexual exposure. J Acquir Immune Defic Syndr 2022;90:27–32. - PubMed
1. Tan DHS, Hull MW, Yoong D, et al. .Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ 2017;189:E1448–58. - PMC - PubMed
1. Coukan F, Murray K-K, Papageorgiou V, et al. . Barriers and facilitators to HIV pre-exposure prophylaxis (PrEP) in specialist sexual health services in the United Kingdom: a systematic review using the PrEP Care Continuum. HIV Med 2023;24:893–913. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Billick MJ, Sheps J, Bogoch II. HIV prevention with postexposure prophylaxis-in-pocket (PIP). BMJ 2023;382:e076016. doi:10.1136/bmj-2023-076016. - DOI - PubMed

[2] Billick MJ, Sheps J, Bogoch II. HIV prevention with postexposure prophylaxis-in-pocket (PIP). BMJ 2023;382:e076016. doi:10.1136/bmj-2023-076016. - DOI - PubMed

[3] Billick MJ, Fisher KN, Myers S, et al. . Brief report: Outcomes of individuals using HIV postexposure prophylaxis-in-pocket (“PIP”) for low-frequency, high-risk exposures in Toronto, Canada. J Acquir Immune Defic Syndr 2023;94:211–3. - PubMed

[4] Billick MJ, Fisher KN, Myers S, et al. . Brief report: Outcomes of individuals using HIV postexposure prophylaxis-in-pocket (“PIP”) for low-frequency, high-risk exposures in Toronto, Canada. J Acquir Immune Defic Syndr 2023;94:211–3. - PubMed

[5] Mayer KH, Gelman M, Holmes J, et al. . Safety and tolerability of once daily coformulated bictegravir, emtricitabine, and tenofovir alafenamide for postexposure prophylaxis after sexual exposure. J Acquir Immune Defic Syndr 2022;90:27–32. - PubMed

[6] Mayer KH, Gelman M, Holmes J, et al. . Safety and tolerability of once daily coformulated bictegravir, emtricitabine, and tenofovir alafenamide for postexposure prophylaxis after sexual exposure. J Acquir Immune Defic Syndr 2022;90:27–32. - PubMed

[7] Tan DHS, Hull MW, Yoong D, et al. .Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ 2017;189:E1448–58. - PMC - PubMed

[8] Tan DHS, Hull MW, Yoong D, et al. .Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ 2017;189:E1448–58. - PMC - PubMed

[9] Coukan F, Murray K-K, Papageorgiou V, et al. . Barriers and facilitators to HIV pre-exposure prophylaxis (PrEP) in specialist sexual health services in the United Kingdom: a systematic review using the PrEP Care Continuum. HIV Med 2023;24:893–913. - PubMed

[10] Coukan F, Murray K-K, Papageorgiou V, et al. . Barriers and facilitators to HIV pre-exposure prophylaxis (PrEP) in specialist sexual health services in the United Kingdom: a systematic review using the PrEP Care Continuum. HIV Med 2023;24:893–913. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

HIV postexposure prophylaxis-in-pocket

Affiliations

HIV postexposure prophylaxis-in-pocket

Authors

Affiliations

Conflict of interest statement

Similar articles

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical